Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
UTHR's Cash-to-Debt is ranked higher than
95% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. UTHR: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
UTHR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.69  Med: 29.82 Max: 15951.56
Current: No Debt
0.69
15951.56
Equity-to-Asset 0.81
UTHR's Equity-to-Asset is ranked higher than
69% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. UTHR: 0.81 )
Ranked among companies with meaningful Equity-to-Asset only.
UTHR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.73 Max: 0.97
Current: 0.81
0.37
0.97
Interest Coverage 234.54
UTHR's Interest Coverage is ranked lower than
69% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. UTHR: 234.54 )
Ranked among companies with meaningful Interest Coverage only.
UTHR' s Interest Coverage Range Over the Past 10 Years
Min: 2.02  Med: 16.2 Max: 272.23
Current: 234.54
2.02
272.23
Piotroski F-Score: 5
Altman Z-Score: 10.88
Beneish M-Score: -2.63
WACC vs ROIC
10.49%
79.83%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 60.09
UTHR's Operating Margin % is ranked higher than
98% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. UTHR: 60.09 )
Ranked among companies with meaningful Operating Margin % only.
UTHR' s Operating Margin % Range Over the Past 10 Years
Min: -29.15  Med: 35.36 Max: 66.41
Current: 60.09
-29.15
66.41
Net Margin % 41.04
UTHR's Net Margin % is ranked higher than
95% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. UTHR: 41.04 )
Ranked among companies with meaningful Net Margin % only.
UTHR' s Net Margin % Range Over the Past 10 Years
Min: -17.52  Med: 22.13 Max: 44.64
Current: 41.04
-17.52
44.64
ROE % 35.41
UTHR's ROE % is ranked higher than
97% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. UTHR: 35.41 )
Ranked among companies with meaningful ROE % only.
UTHR' s ROE % Range Over the Past 10 Years
Min: -11.59  Med: 19.34 Max: 46.03
Current: 35.41
-11.59
46.03
ROA % 28.43
UTHR's ROA % is ranked higher than
98% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. UTHR: 28.43 )
Ranked among companies with meaningful ROA % only.
UTHR' s ROA % Range Over the Past 10 Years
Min: -6.75  Med: 12.09 Max: 32.03
Current: 28.43
-6.75
32.03
ROC (Joel Greenblatt) % 184.22
UTHR's ROC (Joel Greenblatt) % is ranked higher than
96% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. UTHR: 184.22 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
UTHR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -43.1  Med: 79.54 Max: 215.37
Current: 184.22
-43.1
215.37
3-Year Revenue Growth Rate 17.60
UTHR's 3-Year Revenue Growth Rate is ranked higher than
70% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. UTHR: 17.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
UTHR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 17.6  Med: 37.8 Max: 260.9
Current: 17.6
17.6
260.9
3-Year EBITDA Growth Rate 56.00
UTHR's 3-Year EBITDA Growth Rate is ranked higher than
90% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. UTHR: 56.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
UTHR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -56.2  Med: 22.7 Max: 128
Current: 56
-56.2
128
3-Year EPS without NRI Growth Rate 66.90
UTHR's 3-Year EPS without NRI Growth Rate is ranked higher than
94% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. UTHR: 66.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
UTHR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -50.7  Med: 19.7 Max: 153.6
Current: 66.9
-50.7
153.6
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» UTHR's 30-Y Financials

Financials (Next Earnings Date: 2017-10-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

UTHR Guru Trades in Q3 2016

Paul Tudor Jones 10,104 sh (+173.08%)
Ray Dalio 113,805 sh (+77.54%)
Ken Fisher 3,124 sh (+1.03%)
David Dreman 2,670 sh (unchged)
Lee Ainslie 25,910 sh (-3.00%)
Jim Simons 390,100 sh (-3.51%)
Joel Greenblatt 317,358 sh (-13.54%)
» More
Q4 2016

UTHR Guru Trades in Q4 2016

Jim Simons 421,200 sh (+7.97%)
Lee Ainslie 26,210 sh (+1.16%)
Ken Fisher 3,124 sh (unchged)
Joel Greenblatt 166,025 sh (-47.69%)
Ray Dalio 43,905 sh (-61.42%)
Paul Tudor Jones 3,534 sh (-65.02%)
David Dreman 146 sh (-94.53%)
» More
Q1 2017

UTHR Guru Trades in Q1 2017

John Hussman 25,500 sh (New)
Jeremy Grantham 1,500 sh (New)
Caxton Associates 2,200 sh (New)
Ray Dalio 58,092 sh (+32.31%)
Joel Greenblatt 209,140 sh (+25.97%)
Jim Simons 506,200 sh (+20.18%)
Paul Tudor Jones 3,700 sh (+4.70%)
Ken Fisher 3,124 sh (unchged)
David Dreman Sold Out
Lee Ainslie 19,440 sh (-25.83%)
» More
Q2 2017

UTHR Guru Trades in Q2 2017

Ken Fisher 3,169 sh (+1.44%)
» More
» Details

Insider Trades

Latest Guru Trades with UTHR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:KITE, NAS:IONS, NAS:BIVV, NAS:ALNY, NAS:TSRO, NAS:CLVS, NAS:TECH, NAS:NBIX, NAS:SGEN, NAS:EXEL, NAS:BLUE, NAS:PTLA, NAS:ACAD, NAS:PBYI, NAS:ICPT, NAS:NKTR, NAS:SAGE, NAS:JUNO, NAS:AGIO, NYSE:XON » details
Traded in other countries:UTH.Germany,
Headquarter Location:USA
United Therapeutics Corp is engaged in the healthcare sector. Its core offering includes pharmaceutical products to address unmet medical needs of patients.

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The firm is a market leader in two of the three primary drugs classes used to treat PAH. Nearly all of its sales are generated within the U.S. United also markets a pediatric oncology drug.

Ratios

vs
industry
vs
history
PE Ratio 9.11
UTHR's PE Ratio is ranked higher than
89% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. UTHR: 9.11 )
Ranked among companies with meaningful PE Ratio only.
UTHR' s PE Ratio Range Over the Past 10 Years
Min: 4.95  Med: 20.86 Max: 171.34
Current: 9.11
4.95
171.34
Forward PE Ratio 8.77
UTHR's Forward PE Ratio is ranked higher than
87% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 21.98 vs. UTHR: 8.77 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 9.11
UTHR's PE Ratio without NRI is ranked higher than
89% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 31.31 vs. UTHR: 9.11 )
Ranked among companies with meaningful PE Ratio without NRI only.
UTHR' s PE Ratio without NRI Range Over the Past 10 Years
Min: 4.95  Med: 20.86 Max: 171.34
Current: 9.11
4.95
171.34
Price-to-Owner-Earnings 10.52
UTHR's Price-to-Owner-Earnings is ranked higher than
80% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 34.46 vs. UTHR: 10.52 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
UTHR' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.08  Med: 35.83 Max: 577.3
Current: 10.52
5.08
577.3
PB Ratio 2.84
UTHR's PB Ratio is ranked higher than
63% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. UTHR: 2.84 )
Ranked among companies with meaningful PB Ratio only.
UTHR' s PB Ratio Range Over the Past 10 Years
Min: 2.01  Med: 3.75 Max: 10.39
Current: 2.84
2.01
10.39
PS Ratio 3.74
UTHR's PS Ratio is ranked higher than
77% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. UTHR: 3.74 )
Ranked among companies with meaningful PS Ratio only.
UTHR' s PS Ratio Range Over the Past 10 Years
Min: 2.83  Med: 5.43 Max: 11.47
Current: 3.74
2.83
11.47
Price-to-Free-Cash-Flow 8.56
UTHR's Price-to-Free-Cash-Flow is ranked higher than
85% of the 125 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. UTHR: 8.56 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
UTHR' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.84  Med: 18.87 Max: 644.84
Current: 8.56
7.84
644.84
Price-to-Operating-Cash-Flow 7.99
UTHR's Price-to-Operating-Cash-Flow is ranked higher than
84% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. UTHR: 7.99 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
UTHR' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.32  Med: 16.87 Max: 46
Current: 7.99
7.32
46
EV-to-EBIT 4.88
UTHR's EV-to-EBIT is ranked higher than
84% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. UTHR: 4.88 )
Ranked among companies with meaningful EV-to-EBIT only.
UTHR' s EV-to-EBIT Range Over the Past 10 Years
Min: -31.2  Med: 11.2 Max: 122
Current: 4.88
-31.2
122
EV-to-EBITDA 4.72
UTHR's EV-to-EBITDA is ranked higher than
85% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. UTHR: 4.72 )
Ranked among companies with meaningful EV-to-EBITDA only.
UTHR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -33.7  Med: 10.4 Max: 103.2
Current: 4.72
-33.7
103.2
PEG Ratio 0.27
UTHR's PEG Ratio is ranked higher than
94% of the 102 Companies
in the Global Biotechnology industry.

( Industry Median: 2.10 vs. UTHR: 0.27 )
Ranked among companies with meaningful PEG Ratio only.
UTHR' s PEG Ratio Range Over the Past 10 Years
Min: 0.16  Med: 0.36 Max: 2.42
Current: 0.27
0.16
2.42
Shiller PE Ratio 23.95
UTHR's Shiller PE Ratio is ranked higher than
82% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 44.06 vs. UTHR: 23.95 )
Ranked among companies with meaningful Shiller PE Ratio only.
UTHR' s Shiller PE Ratio Range Over the Past 10 Years
Min: 21.93  Med: 46.15 Max: 679.13
Current: 23.95
21.93
679.13
Current Ratio 3.52
UTHR's Current Ratio is ranked lower than
54% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. UTHR: 3.52 )
Ranked among companies with meaningful Current Ratio only.
UTHR' s Current Ratio Range Over the Past 10 Years
Min: 0.96  Med: 5.16 Max: 64.22
Current: 3.52
0.96
64.22
Quick Ratio 3.27
UTHR's Quick Ratio is ranked lower than
54% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. UTHR: 3.27 )
Ranked among companies with meaningful Quick Ratio only.
UTHR' s Quick Ratio Range Over the Past 10 Years
Min: 0.9  Med: 4.91 Max: 64.22
Current: 3.27
0.9
64.22
Days Inventory 402.64
UTHR's Days Inventory is ranked lower than
91% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. UTHR: 402.64 )
Ranked among companies with meaningful Days Inventory only.
UTHR' s Days Inventory Range Over the Past 10 Years
Min: 118.32  Med: 167.09 Max: 455.12
Current: 402.64
118.32
455.12
Days Sales Outstanding 42.88
UTHR's Days Sales Outstanding is ranked higher than
69% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. UTHR: 42.88 )
Ranked among companies with meaningful Days Sales Outstanding only.
UTHR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.71  Med: 45.68 Max: 49.96
Current: 42.88
36.71
49.96
Days Payable 34.26
UTHR's Days Payable is ranked lower than
65% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. UTHR: 34.26 )
Ranked among companies with meaningful Days Payable only.
UTHR' s Days Payable Range Over the Past 10 Years
Min: 18.67  Med: 40.17 Max: 246.85
Current: 34.26
18.67
246.85

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 5.20
UTHR's 3-Year Average Share Buyback Ratio is ranked higher than
99% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. UTHR: 5.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
UTHR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -9.9  Med: -0.85 Max: 5.2
Current: 5.2
-9.9
5.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 8.86
UTHR's Price-to-Net-Cash is ranked lower than
55% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. UTHR: 8.86 )
Ranked among companies with meaningful Price-to-Net-Cash only.
UTHR' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.51  Med: 10.1 Max: 160.03
Current: 8.86
1.51
160.03
Price-to-Net-Current-Asset-Value 5.81
UTHR's Price-to-Net-Current-Asset-Value is ranked higher than
57% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. UTHR: 5.81 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
UTHR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.46  Med: 10.26 Max: 5533
Current: 5.81
1.46
5533
Price-to-Tangible-Book 2.88
UTHR's Price-to-Tangible-Book is ranked higher than
70% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. UTHR: 2.88 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
UTHR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.16  Med: 3.66 Max: 18.16
Current: 2.88
1.16
18.16
Price-to-Intrinsic-Value-Projected-FCF 0.84
UTHR's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
93% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. UTHR: 0.84 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
UTHR' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.83  Med: 2.73 Max: 232.67
Current: 0.84
0.83
232.67
Price-to-Median-PS-Value 0.69
UTHR's Price-to-Median-PS-Value is ranked higher than
70% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. UTHR: 0.69 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
UTHR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.57  Med: 1.47 Max: 299.08
Current: 0.69
0.57
299.08
Price-to-Peter-Lynch-Fair-Value 0.36
UTHR's Price-to-Peter-Lynch-Fair-Value is ranked higher than
97% of the 76 Companies
in the Global Biotechnology industry.

( Industry Median: 1.95 vs. UTHR: 0.36 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
UTHR' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.21  Med: 0.99 Max: 5.82
Current: 0.36
0.21
5.82
Price-to-Graham-Number 1.08
UTHR's Price-to-Graham-Number is ranked higher than
82% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. UTHR: 1.08 )
Ranked among companies with meaningful Price-to-Graham-Number only.
UTHR' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.77  Med: 2.48 Max: 6.18
Current: 1.08
0.77
6.18
Earnings Yield (Greenblatt) % 20.49
UTHR's Earnings Yield (Greenblatt) % is ranked higher than
96% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. UTHR: 20.49 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
UTHR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -5.9  Med: 5.8 Max: 40.2
Current: 20.49
-5.9
40.2
Forward Rate of Return (Yacktman) % 38.13
UTHR's Forward Rate of Return (Yacktman) % is ranked higher than
87% of the 129 Companies
in the Global Biotechnology industry.

( Industry Median: 14.33 vs. UTHR: 38.13 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
UTHR' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -1.4  Med: 1.4 Max: 56.9
Current: 38.13
-1.4
56.9

More Statistics

Revenue (TTM) (Mil) $1,600.30
EPS (TTM) $ 14.27
Beta1.37
Short Percentage of Float15.77%
52-Week Range $110.72 - 169.89
Shares Outstanding (Mil)45.06

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1,617 1,403 1,293
EPS ($) 15.19 12.75 11.98
EPS without NRI ($) 15.19 12.75 11.98
EPS Growth Rate
(Future 3Y To 5Y Estimate)
-7.75%
Dividends per Share ($)
» More Articles for UTHR

Headlines

Articles On GuruFocus.com
United Therapeutics Corporation to Report Second Quarter 2017 Financial Results Before The Market Op Jul 21 2017 
United Therapeutics Exhibits Some Value Jul 20 2017 
7 of the Worst-Performing Stocks in Gurus' Portfolios Jul 07 2017 
Quick Tips on Investing in the Pharmaceutical and Medical Device Industry Jun 25 2017 
Argan and Sturm Ruger Show High Profit and Low Debt Jun 20 2017 
United Therapeutics Corporation To Present At Jefferies 2017 Global Healthcare Conference May 31 2017 
SteadyMed Reports First Quarter 2017 Financial Results and Provides Corporate Update May 12 2017 
United Therapeutics Announces $250 Million Share Repurchase Program Apr 27 2017 
United Therapeutics Corporation Reports First Quarter 2017 Financial Results Apr 26 2017 
3D Systems and United Therapeutics Announce Bioprinting Agreement Apr 26 2017 

More From Other Websites
United Therapeutics Corporation to Report Second Quarter 2017 Financial Results Before The Market... Jul 21 2017
Upcoming Catalysts Could Boost United Therapeutics: OpCo Jul 19 2017
E*Trade Financial, Statoil, Arena Pharmaceuticals, Johnson & Johnson and United Therapeutics... Jul 12 2017
7 of the Worst-Performing Stocks in Gurus' Portfolios Jul 07 2017
What Analysts Recommend for United Therapeutics in June 2017 Jul 04 2017
Cardiome's Partner SteadyMed Submits NDA for PAH Injection Jul 04 2017
Adcirca May Witness Gradual Decline in Revenues Jul 04 2017
United Therapeutics’ Orenitram May Show Revenue Growth in 2017 Jul 04 2017
What Can We Expect from United Therapeutics’ Tyvaso in 2017? Jul 03 2017
How Is United Therapeutics’ Remodulin Positioned in 2017? Jul 03 2017
How United Therapeutics Is Expected to Perform in 2017 Jul 03 2017
[$$] Biotech Blazes Higher Jun 23 2017
Argan and Sturm Ruger Show High Profit and Low Debt Jun 20 2017
Silver Spring tissue regeneration company raises $12 million Jun 14 2017
Your first trade for Friday, June 9 Jun 09 2017
“Fast Money” final trades: KSU, SNAP, and more Jun 08 2017
Here's how the founder of X Prize says you can invest in ... Jun 07 2017
ETFs with exposure to United Therapeutics Corp. : June 2, 2017 Jun 02 2017
United Therapeutics Corp. breached its 50 day moving average in a Bullish Manner : UTHR-US : June 2,... Jun 02 2017
United Therapeutics Corporation To Present At Jefferies 2017 Global Healthcare Conference May 31 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}